Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma.
By A. Stewart, S. Rajkumar, M. Dimopoulos, Tamás Masszi, I. Špička, A. Oriol, R. Hájek, L. Rosiñol, David S. Siegel, G. Mihaylov and 20 more. New England Journal of Medicine, 2015
1,221 citations recorded by the source corpus.
Subfields: Hematology, Molecular Biology
View Paper: https://www.semanticscholar.org/paper/6c229c6500f2d44efe03b42aea66351261666d13
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Hematology
In Molecular Biology
Citations in the corpus
- Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma. (2015, neutral): “Yes No Previous lenalidomide Yes No Previous stem-cell transplantation Yes No Mutations del(17p) 1q21 t(4;14) Baseline creatinine clearance <60 ml/min ≥60 ml/min Elotuzumab Hazard Ratio (95% CI) Control Subgroup”
- 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). (2016, background): “protein complexes responsible for degrading dysfunctional or unneeded proteins, have an important maintenance function in the cardiomyocyte, and cardiac dysfunction and other cardiac issues may be expected if this maintenance function is impaired.(76) The incidence of HF under bortezomib is relative”
- Multiple myeloma: 2020 update on diagnosis, risk‐stratification and management (2020, background): “Stewart et al.(66,137) Rd 396 67 14 18 40 .”
- 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines (2016, background): “protein complexes responsible for degrading dysfunctional or unneeded proteins, have an important maintenance function in the cardiomyocyte, and cardiac dysfunction and other cardiac issues may be expected if this maintenance function is impaired.(76) The incidence of HF under bortezomib is relative”
- Chemotherapy-Induced Peripheral Neuropathy: A Current Review (2017, background): “CIPN is a common clinical problem; approximately 30 to 40% of patients receiving neurotoxic chemotherapy will suffer from this condition, and it significantly increases the annual costs of health care.1 Several classical chemotherapeutics (platinum, vinca alkaloids, taxanes) are well-established cau”
- Multiple myeloma: 2022 update on diagnosis, risk stratification, and management (2022, background): “effective in a randomized trial, and is a major option for the treatment of relapsed disease (Table 8).(65) In another randomized trial, carfilzomib plus dexamethasone was associated with an improvement in PFS and OS compared with bortezomib plus dexamethasone in relapsed multiple myeloma.”